BIB
ProShares Ultra Nasdaq Biotechnology
NAV as of
4 Week: 41.74 - 48.20
52 Week: 40.35 - 62.61
Latest Closing Price
47.55
Premium / Discount
0.04
Expense Ratio
0.95%
Investment Objective
The investment seeks daily investment results that correspond to two times (2x) the daily performance of the Nasdaq Biotechnology Index®. The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the Daily Target. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Main Fund Characteristics
Performance
| Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
|---|---|---|---|
| YTD | -17.59 | 1.98 | -8.88 |
| 1 Day | -1.35 | 0.00 | 0.00 |
| 1 Week | 2.27 | 2.78 | 0.82 |
| 1 Month | 7.55 | 10.04 | 0.75 |
| 3 Months | -7.51 | 16.99 | -0.44 |
| 6 Months | -13.01 | 20.69 | -0.63 |
| 1 Year | -23.08 | 32.27 | -0.72 |
| 2 Years | -42.22 | 65.79 | -0.64 |
| 3 Years | -44.12 | 78.56 | -0.56 |
| 5 Years | -3.31 | 112.40 | -0.03 |
| 10 Years | -67.28 | 188.11 | -0.36 |
Price History
Annual Performance Return
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
| Price (%) | 160.1382 | 66.6976 | 13.7964 | -44.2251 | 40.7379 | -24.3624 | 45.5046 | 39.7412 | -5.9111 | -28.6357 |
| Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
| Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Dividend Frequency
Lastest Dividend
| Ex Date | Payment Date | Dividend Payout per unit |
|---|---|---|
| 21/12/2022 | 29/12/2022 | 0.0198 |
| 20/09/2010 | 27/09/2010 | 0.0439 |
Portfolio Data
Total Number of Holdings: 263
Number of Bond Holdings: 0
Number of Equity Holdings: 262
Total Market Value: 82,999,313
Portfolio Composition
Top 10 Holdings
| % Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
|---|---|---|---|---|---|
| 1 | Amgen Inc | 7.6088 | 20,457 | 0 | 5,431,743 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
| Size | % of portfolio |
|---|---|
| Giant | 5.17 |
| Large | 29.37 |
| Medium | 22.31 |
| Small | 12.63 |
| Micro | 9.40 |
Equity Style Box Breakdown
| 0 | 0 | 0 | Large |
| 0 | 0 | 0 | Mid |
| 0 | 0 | 0 | Small |
| Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
14.1840
Price/Book*
2.9061
Price/Sales*
3.8933
Price/Cash Flow*
12.2845
Dividend Yield*
1.0207
Growth Measures
Long-Term Earnings
5.8734
Historical Earnings
3.2155
Sales Growth
11.8316
Cash-Flow Growth
6.6256
Book-Value Growth
6.3221
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
| Detail | Value |
|---|---|
| Average Effective Duration | 0 |
| Average Effective Maturity (Years)* | 0 |
| Average Credit Quality | 0 |
| Average Weighted Coupon* | 0 |
| Average Weighted Price* | 0 |
Bond Style Box Breakdown
| 0 | 0 | 0 | High | Quality |
| 0 | 0 | 0 | Med | |
| 0 | 0 | 0 | Low | |
| Ltd | Mod | Ext | ||
| Interest-Rate Sensitivity | ||||
Credit Quality
| Type | % Bonds |
|---|---|
| N.A | |
Bond Sector
Bond Maturity
| % Bonds | |
|---|---|
| N.A | |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.
